How High Will Brown Forman Stock Go?
On the surface, Brown‑Forman (NYSE: BF.B) is having an unremarkable year.…
Sell
30
TRIB Quote, Financials, Valuation and Earnings
Last price:
$0.73
Seasonality move
:
-9.8%
Day range:
$0.71 - $0.75
52-week range:
$0.48 - $3.44
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.15x
P/B ratio:
--
Volume:
32.6K
Avg. volume:
1.6M
1-year change:
-76.28%
Market cap:
$13.6M
Revenue:
$61.6M
EPS (TTM):
-$2.28
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TRIB
Trinity Biotech PLC
|
$7.5M | -$0.57 | -33.73% | -29.75% | -- |
|
ADAP
Adaptimmune Therapeutics PLC
|
$11.1M | -$0.14 | -91.39% | -8.33% | $1.45 |
|
AMRN
Amarin Corp PLC
|
$53.4M | -$0.61 | -20.31% | -- | $10.50 |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | $17.94 |
|
CLLS
Cellectis SA
|
$11.7M | -$0.15 | 39.85% | -46.43% | $5.75 |
|
DBVT
DBV Technologies SA
|
$747.8K | -$0.18 | -- | -84.24% | $16.06 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TRIB
Trinity Biotech PLC
|
$0.73 | -- | $13.6M | -- | $0.00 | 0% | 0.15x |
|
ADAP
Adaptimmune Therapeutics PLC
|
$0.28 | $1.45 | $74.1M | -- | $0.00 | 0% | 0.40x |
|
AMRN
Amarin Corp PLC
|
$15.82 | $10.50 | $327.6M | -- | $0.00 | 0% | 1.53x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
$0.84 | $17.94 | $4.3M | -- | $0.00 | 0% | 0.88x |
|
CLLS
Cellectis SA
|
$1.82 | $5.75 | $182.6M | -- | $0.00 | 0% | 3.73x |
|
DBVT
DBV Technologies SA
|
$10.00 | $16.06 | $273.5M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TRIB
Trinity Biotech PLC
|
147.47% | -1.876 | 785.94% | 0.87x |
|
ADAP
Adaptimmune Therapeutics PLC
|
-211.44% | 3.289 | 50.03% | 1.57x |
|
AMRN
Amarin Corp PLC
|
-- | 1.987 | -- | 2.39x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | 2.010 | -- | 1.20x |
|
CLLS
Cellectis SA
|
30.41% | 0.887 | 56.64% | 1.64x |
|
DBVT
DBV Technologies SA
|
-- | -2.552 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TRIB
Trinity Biotech PLC
|
$5.3M | -$2.2M | -45.03% | -- | -11.29% | -$6.3M |
|
ADAP
Adaptimmune Therapeutics PLC
|
$6.4M | -$44.1M | -107.36% | -199.63% | -619.47% | -$67.8M |
|
AMRN
Amarin Corp PLC
|
$25.1M | -$16.8M | -16.98% | -16.98% | -39.88% | -$12.5M |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
CLLS
Cellectis SA
|
$8.6M | -$14.2M | -35.55% | -49.15% | -152.19% | -$17.6M |
|
DBVT
DBV Technologies SA
|
-- | -$26.6M | -- | -- | -- | -$19.7M |
Trinity Biotech PLC vs. Competitors
-
Which has Higher Returns TRIB or ADAP?
Adaptimmune Therapeutics PLC has a net margin of -31.41% compared to Trinity Biotech PLC's net margin of -653.18%. Trinity Biotech PLC's return on equity of -- beat Adaptimmune Therapeutics PLC's return on equity of -199.63%.
Company Gross Margin Earnings Per Share Invested Capital TRIBTrinity Biotech PLC35.03% -$0.46 $55.5M ADAPAdaptimmune Therapeutics PLC87.93% -$0.18 -$12M -
What do Analysts Say About TRIB or ADAP?
Trinity Biotech PLC has a consensus price target of --, signalling upside risk potential of 1952.83%. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $1.45 which suggests that it could grow by 419.23%. Given that Trinity Biotech PLC has higher upside potential than Adaptimmune Therapeutics PLC, analysts believe Trinity Biotech PLC is more attractive than Adaptimmune Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings TRIBTrinity Biotech PLC0 0 0 ADAPAdaptimmune Therapeutics PLC2 4 0 -
Is TRIB or ADAP More Risky?
Trinity Biotech PLC has a beta of 0.804, which suggesting that the stock is 19.628% less volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.179, suggesting its more volatile than the S&P 500 by 117.923%.
-
Which is a Better Dividend Stock TRIB or ADAP?
Trinity Biotech PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trinity Biotech PLC pays -- of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TRIB or ADAP?
Trinity Biotech PLC quarterly revenues are $15.2M, which are larger than Adaptimmune Therapeutics PLC quarterly revenues of $7.3M. Trinity Biotech PLC's net income of -$4.8M is higher than Adaptimmune Therapeutics PLC's net income of -$47.6M. Notably, Trinity Biotech PLC's price-to-earnings ratio is -- while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trinity Biotech PLC is 0.15x versus 0.40x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TRIBTrinity Biotech PLC0.15x -- $15.2M -$4.8M ADAPAdaptimmune Therapeutics PLC0.40x -- $7.3M -$47.6M
-
Which has Higher Returns TRIB or AMRN?
Amarin Corp PLC has a net margin of -31.41% compared to Trinity Biotech PLC's net margin of -37.36%. Trinity Biotech PLC's return on equity of -- beat Amarin Corp PLC's return on equity of -16.98%.
Company Gross Margin Earnings Per Share Invested Capital TRIBTrinity Biotech PLC35.03% -$0.46 $55.5M AMRNAmarin Corp PLC59.81% -$0.80 $473.7M -
What do Analysts Say About TRIB or AMRN?
Trinity Biotech PLC has a consensus price target of --, signalling upside risk potential of 1952.83%. On the other hand Amarin Corp PLC has an analysts' consensus of $10.50 which suggests that it could fall by -33.63%. Given that Trinity Biotech PLC has higher upside potential than Amarin Corp PLC, analysts believe Trinity Biotech PLC is more attractive than Amarin Corp PLC.
Company Buy Ratings Hold Ratings Sell Ratings TRIBTrinity Biotech PLC0 0 0 AMRNAmarin Corp PLC0 1 1 -
Is TRIB or AMRN More Risky?
Trinity Biotech PLC has a beta of 0.804, which suggesting that the stock is 19.628% less volatile than S&P 500. In comparison Amarin Corp PLC has a beta of 0.823, suggesting its less volatile than the S&P 500 by 17.66%.
-
Which is a Better Dividend Stock TRIB or AMRN?
Trinity Biotech PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amarin Corp PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trinity Biotech PLC pays -- of its earnings as a dividend. Amarin Corp PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TRIB or AMRN?
Trinity Biotech PLC quarterly revenues are $15.2M, which are smaller than Amarin Corp PLC quarterly revenues of $42M. Trinity Biotech PLC's net income of -$4.8M is higher than Amarin Corp PLC's net income of -$15.7M. Notably, Trinity Biotech PLC's price-to-earnings ratio is -- while Amarin Corp PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trinity Biotech PLC is 0.15x versus 1.53x for Amarin Corp PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TRIBTrinity Biotech PLC0.15x -- $15.2M -$4.8M AMRNAmarin Corp PLC1.53x -- $42M -$15.7M
-
Which has Higher Returns TRIB or BDRX?
Biodexa Pharmaceuticals PLC has a net margin of -31.41% compared to Trinity Biotech PLC's net margin of --. Trinity Biotech PLC's return on equity of -- beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital TRIBTrinity Biotech PLC35.03% -$0.46 $55.5M BDRXBiodexa Pharmaceuticals PLC-- -- $6M -
What do Analysts Say About TRIB or BDRX?
Trinity Biotech PLC has a consensus price target of --, signalling upside risk potential of 1952.83%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.94 which suggests that it could grow by 2024.55%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Trinity Biotech PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Trinity Biotech PLC.
Company Buy Ratings Hold Ratings Sell Ratings TRIBTrinity Biotech PLC0 0 0 BDRXBiodexa Pharmaceuticals PLC1 0 0 -
Is TRIB or BDRX More Risky?
Trinity Biotech PLC has a beta of 0.804, which suggesting that the stock is 19.628% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.167, suggesting its more volatile than the S&P 500 by 16.654%.
-
Which is a Better Dividend Stock TRIB or BDRX?
Trinity Biotech PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trinity Biotech PLC pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TRIB or BDRX?
Trinity Biotech PLC quarterly revenues are $15.2M, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. Trinity Biotech PLC's net income of -$4.8M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Trinity Biotech PLC's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trinity Biotech PLC is 0.15x versus 0.88x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TRIBTrinity Biotech PLC0.15x -- $15.2M -$4.8M BDRXBiodexa Pharmaceuticals PLC0.88x -- -- --
-
Which has Higher Returns TRIB or CLLS?
Cellectis SA has a net margin of -31.41% compared to Trinity Biotech PLC's net margin of -170.14%. Trinity Biotech PLC's return on equity of -- beat Cellectis SA's return on equity of -49.15%.
Company Gross Margin Earnings Per Share Invested Capital TRIBTrinity Biotech PLC35.03% -$0.46 $55.5M CLLSCellectis SA81.09% -$0.18 $167M -
What do Analysts Say About TRIB or CLLS?
Trinity Biotech PLC has a consensus price target of --, signalling upside risk potential of 1952.83%. On the other hand Cellectis SA has an analysts' consensus of $5.75 which suggests that it could grow by 215.93%. Given that Trinity Biotech PLC has higher upside potential than Cellectis SA, analysts believe Trinity Biotech PLC is more attractive than Cellectis SA.
Company Buy Ratings Hold Ratings Sell Ratings TRIBTrinity Biotech PLC0 0 0 CLLSCellectis SA1 2 0 -
Is TRIB or CLLS More Risky?
Trinity Biotech PLC has a beta of 0.804, which suggesting that the stock is 19.628% less volatile than S&P 500. In comparison Cellectis SA has a beta of 2.910, suggesting its more volatile than the S&P 500 by 191%.
-
Which is a Better Dividend Stock TRIB or CLLS?
Trinity Biotech PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trinity Biotech PLC pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TRIB or CLLS?
Trinity Biotech PLC quarterly revenues are $15.2M, which are larger than Cellectis SA quarterly revenues of $10.7M. Trinity Biotech PLC's net income of -$4.8M is higher than Cellectis SA's net income of -$18.1M. Notably, Trinity Biotech PLC's price-to-earnings ratio is -- while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trinity Biotech PLC is 0.15x versus 3.73x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TRIBTrinity Biotech PLC0.15x -- $15.2M -$4.8M CLLSCellectis SA3.73x -- $10.7M -$18.1M
-
Which has Higher Returns TRIB or DBVT?
DBV Technologies SA has a net margin of -31.41% compared to Trinity Biotech PLC's net margin of --. Trinity Biotech PLC's return on equity of -- beat DBV Technologies SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TRIBTrinity Biotech PLC35.03% -$0.46 $55.5M DBVTDBV Technologies SA-- -$1.30 -- -
What do Analysts Say About TRIB or DBVT?
Trinity Biotech PLC has a consensus price target of --, signalling upside risk potential of 1952.83%. On the other hand DBV Technologies SA has an analysts' consensus of $16.06 which suggests that it could grow by 61.39%. Given that Trinity Biotech PLC has higher upside potential than DBV Technologies SA, analysts believe Trinity Biotech PLC is more attractive than DBV Technologies SA.
Company Buy Ratings Hold Ratings Sell Ratings TRIBTrinity Biotech PLC0 0 0 DBVTDBV Technologies SA1 0 0 -
Is TRIB or DBVT More Risky?
Trinity Biotech PLC has a beta of 0.804, which suggesting that the stock is 19.628% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.587, suggesting its less volatile than the S&P 500 by 158.693%.
-
Which is a Better Dividend Stock TRIB or DBVT?
Trinity Biotech PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trinity Biotech PLC pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TRIB or DBVT?
Trinity Biotech PLC quarterly revenues are $15.2M, which are larger than DBV Technologies SA quarterly revenues of --. Trinity Biotech PLC's net income of -$4.8M is higher than DBV Technologies SA's net income of -$27.1M. Notably, Trinity Biotech PLC's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trinity Biotech PLC is 0.15x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TRIBTrinity Biotech PLC0.15x -- $15.2M -$4.8M DBVTDBV Technologies SA-- -- -- -$27.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Bloom Energy Flying Under the Radar?
Bloom Energy (NYSE:BE) manufactures scalable fuel cells for providing on-site…
Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
61
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Alerts
Buy
55
TLN alert for Jul 19
Talen Energy [TLN] is up 24.44% over the past day.
Sell
48
CRSP alert for Jul 19
CRISPR Therapeutics AG [CRSP] is up 18.22% over the past day.
Buy
83
SOC alert for Jul 19
Sable Offshore [SOC] is up 11.86% over the past day.
